

CLAIMS

1. An isolated antibody or antigen-binding fragment thereof binding to human Sema3A, wherein said isolated antibody or antigen-binding fragment thereof
 - i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD) ≤ 50 nM, ≤ 20 nM, ≤ 10 nM, ≤ 1 nM, or ≤ 0.1 nM;
 - ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD) ≤ 50 nM, ≤ 20 nM, ≤ 10 nM, ≤ 1 nM, or ≤ 0.1 nM;
 - iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of $\geq 60\%$, $\geq 70\%$, $\geq 80\%$, or $\geq 90\%$;
 - iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC₅₀ of ≤ 10 nM, ≤ 5 nM, ≤ 2.5 nM, or ≤ 1 nM;
 - v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC₅₀ of ≤ 50 nM, ≤ 25 nM, ≤ 10 nM, or ≤ 5 nM; and/or
 - vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC₅₀ of ≤ 1 nM, or ≤ 0.3 nM, ≤ 0.1 nM, ≤ 0.07 nM, ≤ 0.06 nM
2. The isolated antibody or antigen-binding fragment according to claim 1, wherein said isolated antibody or antigen-binding fragment thereof cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly having an affinity to mouse, cynomolgus, rat, pig and/or dog Sema3A that is less than 100-fold, particularly less than 50-fold, more particularly less than 25-fold, even more particularly less than 10-fold and most particularly less than 5-fold different to that to human Sema3A.
3. The isolated antibody or antigen-binding fragment according to claim 1 or 2, wherein said isolated antibody or antigen-binding fragment thereof does not significantly cross-react with human Sema3B, Sema3C, Sema3D, Sema3E, Sema3F and/or Sema3G, in particular wherein said isolated antibody or antigen-binding fragment thereof does not significantly cross-react

with human Sema3G.

4. The isolated antibody or antigen-binding fragment according to any one of the preceding claims, wherein said isolated antibody or antigen-binding fragment thereof inhibits Sema3A induced albuminuria and/or proteinuria.
5. The isolated antibody or antigen-binding fragment according to any one of the preceding claims, wherein said isolated antibody or antigen-binding fragment thereof inhibits Sema3A induced fibrosis.
6. An isolated antibody or antigen-binding fragment thereof that competes with the isolated antibody or antigen-binding fragment according to any one of the preceding claims for binding to Sema3A and wherein the isolated antibody or antigen-binding fragment does not compete with the binding of an antibody comprising i) the SEQ IDs NO:800 and NO: 804 or ii) NO: 810 and NO: 811 to Sema3A.
7. The isolated antibody or antigen-binding fragment according to anyone of claims 1 or 2 comprising
 - i) a heavy chain variable domain that is at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 141, and a light chain variable domain that is at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 145; or
 - ii) a heavy chain variable domain that is at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 61, and a light chain variable domain that is at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 65.
8. The isolated antibody or antigen-binding fragment according to any one of the preceding claims comprising
 - i) a) a heavy chain antigen-binding region that comprises an H-CDR3 comprising the sequence RDDYTSRDAFDX (SEQ ID NO: 594), wherein X is selected from the group consisting of Y and V, particularly wherein X is Y; and b) a light chain antigen-binding region that comprises an L-CDR3 comprising the sequence X₁AWDDSLNX₂X₃X₄V (SEQ ID NO: 598), wherein X₁ is selected from the group consisting of A and H; wherein X₂ is selected from the group consisting of V, D, and G, in particular wherein X₂ is selected from the group consisting of V and D; wherein X₃ is selected from the group consisting of I and Y; and wherein

X₄ is selected from the group consisting of P and V; or

- ii) a) a heavy chain antigen-binding region that comprises an H-CDR3 comprising the sequence SGYSSSWFDPDFDY (SEQ ID NO: 64); and b) a light chain antigen-binding region that comprises an L-CDR3 comprising the sequence X₁SYX₂GX₃NPYVV (SEQ ID NO: 599), wherein X₁ is selected from the group consisting of S and Q; wherein X₂ is selected from the group consisting of E and A; and wherein X₃ is selected from the group consisting of P, I, and S, in particular wherein X₃ is selected from the group consisting of P and I.
9. The isolated antibody or antigen-binding fragment according to any one of the preceding claims comprising
- i) a) a heavy chain antigen-binding region that comprises an H-CDR1 comprising the sequence SYX₁MX₂ (SEQ ID NO: 588), wherein X₁ is selected from G and A and wherein X₂ is selected from H, S and L; particularly an H-CDR1 comprising the sequence SYAMX (SEQ ID NO: 589), wherein X is selected from S and L; an H-CDR2 comprising the sequence AIGX₁GGDTYYADSVX₂G (SEQ ID NO: 590), wherein X₁ is selected from T and Y, and wherein X₂ is selected from K and M; particularly an H-CDR2 comprising the sequence AIGXGGDTYYADSVKG (SEQ ID NO: 591), wherein X is selected from T and Y; and an H-CDR3 comprising the sequence RDDYTSRDAFDX (SEQ ID NO: 594), wherein X is selected from the group consisting of Y and V, particularly wherein X is Y; and b) a light chain antigen-binding region that comprises an L-CDR1 comprising the sequence SGSSSNIGSNTVN (SEQ ID NO: 46); an L-CDR2 comprising the sequence YDDLXPS (SEQ ID NO: 596), wherein X is selected from L and R; particularly an L-CDR2 comprising the sequence YDDLRLPS (SEQ ID NO: 127); and an L-CDR3 comprising the sequence X₁AWDDSLNX₂X₃X₄V (SEQ ID NO: 598), wherein X₁ is selected from the group consisting of A and H; wherein X₂ is selected from the group consisting of V, D, and G, in particular wherein X₂ is selected from the group consisting of V and D; wherein X₃ is selected from the group consisting of I and Y; and wherein X₄ is selected from the group consisting of P and V; or
 - ii) a) a heavy chain antigen-binding region that comprises an H-CDR1 comprising the sequence SYEMN (SEQ ID NO: 62); an H-CDR2 comprising the sequence GISWNSGX₁IX₂YADSVKG (SEQ ID NO: 592), wherein X₁ is selected from W and S and X₂ is selected from G and D; in particular an H-CDR2 comprising the

sequence GISWNSGWIXYADSVKG (SEQ ID NO: 593), wherein X is selected from G and D; and an H-CDR3 comprising the sequence SGYSSSWFDPDFDY (SEQ ID NO: 64); and b) a light chain antigen-binding region that comprises an L-CDR1 comprising the sequence TGSSSXIGAGYDVH (SEQ ID NO: 595), wherein X is selected from N and D; an L-CDR2 comprising the sequence GXSNRPS (SEQ ID NO: 597), wherein X is selected from N and A; and an L-CDR3 comprising the sequence X₁SYX₂GX₃NPYVV (SEQ ID NO: 599), wherein X₁ is selected from the group consisting of S and Q; wherein X₂ is selected from the group consisting of E and A; and wherein X₃ is selected from the group consisting of P, I, and S, in particular wherein X₃ is selected from the group consisting of P and I.

- 10.** The isolated antibody or antigen-binding fragment according to claim 8, wherein in the isolated antibody or antigen-binding fragment according to option i) of claim 8 the amino acid residue directly adjacent to the H-CDR1 at its 5' end is S or Y; or wherein in the isolated antibody or antigen-binding fragment according to option ii) of claim 8 the three amino acid residues directly adjacent to the H-CDR1 at its 5' end are X₁FX₂, wherein X₁ is selected from T and D and X₂ is selected from S and D.
- 11.** The isolated antibody or antigen-binding fragment according to any one of the preceding claims comprising
- i) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 42, an H-CDR2 comprising SEQ ID NO: 43, and an H-CDR3 comprising SEQ ID NO: 44 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 46, an L-CDR2 comprising SEQ ID NO: 47, and an L-CDR3 comprising SEQ ID NO: 48; or
 - ii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 62, an H-CDR2 comprising SEQ ID NO: 63, and an H-CDR3 comprising SEQ ID NO: 64 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 66, an L-CDR2 comprising SEQ ID NO: 67, and an L-CDR3 comprising SEQ ID NO: 68; or
 - iii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 102, an H-CDR2 comprising SEQ ID NO: 103, and an H-CDR3 comprising SEQ ID NO: 104 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 106, an L-CDR2 comprising SEQ

- ID NO: 107, and an L-CDR3 comprising SEQ ID NO: 108; or
- iv) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 122, an H-CDR2 comprising SEQ ID NO: 123, and an H-CDR3 comprising SEQ ID NO: 124 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 126, an L-CDR2 comprising SEQ ID NO: 127, and an L-CDR3 comprising SEQ ID NO: 128; or
 - v) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 142, an H-CDR2 comprising SEQ ID NO: 143, and an H-CDR3 comprising SEQ ID NO: 144 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 146, an L-CDR2 comprising SEQ ID NO: 147, and an L-CDR3 comprising SEQ ID NO: 148; or
 - vi) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 162, an H-CDR2 comprising SEQ ID NO: 163, and an H-CDR3 comprising SEQ ID NO: 164 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 166, an L-CDR2 comprising SEQ ID NO: 167, and an L-CDR3 comprising SEQ ID NO: 168; or
 - vii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 182, an H-CDR2 comprising SEQ ID NO: 183, and an H-CDR3 comprising SEQ ID NO: 184 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 186, an L-CDR2 comprising SEQ ID NO: 187, and an L-CDR3 comprising SEQ ID NO: 188; or
 - viii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 202, an H-CDR2 comprising SEQ ID NO: 203, and an H-CDR3 comprising SEQ ID NO: 204 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 206, an L-CDR2 comprising SEQ ID NO: 207, and an L-CDR3 comprising SEQ ID NO: 208; or
 - ix) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 222, an H-CDR2 comprising SEQ ID NO: 223, and an H-CDR3 comprising SEQ ID NO: 224 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 226, an L-CDR2 comprising SEQ ID NO: 227, and an L-CDR3 comprising SEQ ID NO: 228; or
 - x) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ

- ID NO: 242, an H-CDR2 comprising SEQ ID NO: 243, and an H-CDR3 comprising SEQ ID NO: 244 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 246, an L-CDR2 comprising SEQ ID NO: 247, and an L-CDR3 comprising SEQ ID NO: 248; or
- xi) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 262, an H-CDR2 comprising SEQ ID NO: 263, and an H-CDR3 comprising SEQ ID NO: 264 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 266, an L-CDR2 comprising SEQ ID NO: 267, and an L-CDR3 comprising SEQ ID NO: 268; or
- xii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 282, an H-CDR2 comprising SEQ ID NO: 283, and an H-CDR3 comprising SEQ ID NO: 284 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 286, an L-CDR2 comprising SEQ ID NO: 287, and an L-CDR3 comprising SEQ ID NO: 288; or
- xiii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 302, an H-CDR2 comprising SEQ ID NO: 303, and an H-CDR3 comprising SEQ ID NO: 304 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 306, an L-CDR2 comprising SEQ ID NO: 307, and an L-CDR3 comprising SEQ ID NO: 308; or
- xiv) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 322, an H-CDR2 comprising SEQ ID NO: 323, and an H-CDR3 comprising SEQ ID NO: 324 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 326, an L-CDR2 comprising SEQ ID NO: 327, and an L-CDR3 comprising SEQ ID NO: 328; or
- xv) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 342, an H-CDR2 comprising SEQ ID NO: 343, and an H-CDR3 comprising SEQ ID NO: 344 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 346, an L-CDR2 comprising SEQ ID NO: 347, and an L-CDR3 comprising SEQ ID NO: 348; or
- xvi) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 362, an H-CDR2 comprising SEQ ID NO: 363, and an H-CDR3 comprising SEQ ID NO: 364 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 366, an L-CDR2 comprising SEQ

- ID NO: 367, and an L-CDR3 comprising SEQ ID NO: 368; or
- xvii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 382, an H-CDR2 comprising SEQ ID NO: 383, and an H-CDR3 comprising SEQ ID NO: 384 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 386, an L-CDR2 comprising SEQ ID NO: 387, and an L-CDR3 comprising SEQ ID NO: 388; or
 - xviii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 402, an H-CDR2 comprising SEQ ID NO: 403, and an H-CDR3 comprising SEQ ID NO: 404 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 406, an L-CDR2 comprising SEQ ID NO: 407, and an L-CDR3 comprising SEQ ID NO: 408; or
 - xix) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 422, an H-CDR2 comprising SEQ ID NO: 423, and an H-CDR3 comprising SEQ ID NO: 424 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 426, an L-CDR2 comprising SEQ ID NO: 427, and an L-CDR3 comprising SEQ ID NO: 428; or
 - xx) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 442, an H-CDR2 comprising SEQ ID NO: 443, and an H-CDR3 comprising SEQ ID NO: 444 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 446, an L-CDR2 comprising SEQ ID NO: 447, and an L-CDR3 comprising SEQ ID NO: 448; or
 - xxi) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 462, an H-CDR2 comprising SEQ ID NO: 463, and an H-CDR3 comprising SEQ ID NO: 464 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 466, an L-CDR2 comprising SEQ ID NO: 467, and an L-CDR3 comprising SEQ ID NO: 468; or
 - xxii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 482, an H-CDR2 comprising SEQ ID NO: 483, and an H-CDR3 comprising SEQ ID NO: 484 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 486, an L-CDR2 comprising SEQ ID NO: 487, and an L-CDR3 comprising SEQ ID NO: 488; or
 - xxiii) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ

ID NO: 502, an H-CDR2 comprising SEQ ID NO: 503, and an H-CDR3 comprising SEQ ID NO: 504 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 506, an L-CDR2 comprising SEQ ID NO: 507, and an L-CDR3 comprising SEQ ID NO: 508; or

xxiv) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 522, an H-CDR2 comprising SEQ ID NO: 523, and an H-CDR3 comprising SEQ ID NO: 524 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 526, an L-CDR2 comprising SEQ ID NO: 527, and an L-CDR3 comprising SEQ ID NO: 528; or

xxv) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 542, an H-CDR2 comprising SEQ ID NO: 543, and an H-CDR3 comprising SEQ ID NO: 544 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 546, an L-CDR2 comprising SEQ ID NO: 547, and an L-CDR3 comprising SEQ ID NO: 548; or

xxvi) a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 562, an H-CDR2 comprising SEQ ID NO: 563, and an H-CDR3 comprising SEQ ID NO: 564 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 566, an L-CDR2 comprising SEQ ID NO: 567, and an L-CDR3 comprising SEQ ID NO: 568.

12. The isolated antibody or antigen-binding fragment according to any one of the preceding claims comprising

i) a variable heavy chain domain comprising SEQ ID NO: 41 and a variable light chain domain comprising SEQ ID NO: 45; or

ii) a variable heavy chain domain comprising SEQ ID NO: 61 and a variable light chain domain comprising SEQ ID NO: 65; or

iii) a variable heavy chain domain comprising SEQ ID NO: 101 and a variable light chain domain comprising SEQ ID NO: 105; or

iv) a variable heavy chain domain comprising SEQ ID NO: 121 and a variable light chain domain comprising SEQ ID NO: 125; or

v) a variable heavy chain domain comprising SEQ ID NO: 141 and a variable light chain domain comprising SEQ ID NO: 145; or

- vi) a variable heavy chain domain comprising SEQ ID NO: 161 and a variable light chain domain comprising SEQ ID NO: 165; or
- vii) a variable heavy chain domain comprising SEQ ID NO: 181 and a variable light chain domain comprising SEQ ID NO: 185; or
- viii) a variable heavy chain domain comprising SEQ ID NO: 201 and a variable light chain domain comprising SEQ ID NO: 205; or
- ix) a variable heavy chain domain comprising SEQ ID NO: 221 and a variable light chain domain comprising SEQ ID NO: 225; or
- x) a variable heavy chain domain comprising SEQ ID NO: 241 and a variable light chain domain comprising SEQ ID NO: 245; or
- xi) a variable heavy chain domain comprising SEQ ID NO: 261 and a variable light chain domain comprising SEQ ID NO: 265; or
- xii) a variable heavy chain domain comprising SEQ ID NO: 281 and a variable light chain domain comprising SEQ ID NO: 285; or
- xiii) a variable heavy chain domain comprising SEQ ID NO: 301 and a variable light chain domain comprising SEQ ID NO: 305; or
- xiv) a variable heavy chain domain comprising SEQ ID NO: 321 and a variable light chain domain comprising SEQ ID NO: 325; or
- xv) a variable heavy chain domain comprising SEQ ID NO: 341 and a variable light chain domain comprising SEQ ID NO: 345; or
- xvi) a variable heavy chain domain comprising SEQ ID NO: 361 and a variable light chain domain comprising SEQ ID NO: 365; or
- xvii) a variable heavy chain domain comprising SEQ ID NO: 381 and a variable light chain domain comprising SEQ ID NO: 385; or
- xviii) a variable heavy chain domain comprising SEQ ID NO: 401 and a variable light chain domain comprising SEQ ID NO: 405; or
- xix) a variable heavy chain domain comprising SEQ ID NO: 421 and a variable light chain domain comprising SEQ ID NO: 425; or

- xx) a variable heavy chain domain comprising SEQ ID NO: 441 and a variable light chain domain comprising SEQ ID NO: 445; or
 - xxi) a variable heavy chain domain comprising SEQ ID NO: 461 and a variable light chain domain comprising SEQ ID NO: 465; or
 - xxii) a variable heavy chain domain comprising SEQ ID NO: 481 and a variable light chain domain comprising SEQ ID NO: 485; or
 - xxiii) a variable heavy chain domain comprising SEQ ID NO: 501 and a variable light chain domain comprising SEQ ID NO: 505; or
 - xxiv) a variable heavy chain domain comprising SEQ ID NO: 521 and a variable light chain domain comprising SEQ ID NO: 525; or
 - xxv) a variable heavy chain domain comprising SEQ ID NO: 541 and a variable light chain domain comprising SEQ ID NO: 545; or
 - xxvi) a variable heavy chain domain comprising SEQ ID NO: 561 and a variable light chain domain comprising SEQ ID NO: 565.
13. The isolated antibody according to any one of the preceding claims, which is an IgG antibody, in particular an IgG1 or an IgG4 antibody.
14. The isolated antibody according to any one of the preceding claims comprising
- i) a heavy chain comprising SEQ ID NO: 57 and a light chain comprising SEQ ID NO: 58; or
 - ii) a heavy chain comprising SEQ ID NO: 77 and a light chain comprising SEQ ID NO: 78; or
 - iii) a heavy chain comprising SEQ ID NO: 117 and a light chain comprising SEQ ID NO: 118; or
 - iv) a heavy chain comprising SEQ ID NO: 137 and a light chain comprising SEQ ID NO: 138; or
 - v) a heavy chain comprising SEQ ID NO: 157 and a light chain comprising SEQ ID NO: 158; or
 - vi) a heavy chain comprising SEQ ID NO: 177 and a light chain comprising SEQ ID NO: 178; or

- NO: 178; or
- vii) a heavy chain comprising SEQ ID NO: 197 and a light chain comprising SEQ ID NO: 198; or
 - viii) a heavy chain comprising SEQ ID NO: 217 and a light chain comprising SEQ ID NO: 218; or
 - ix) a heavy chain comprising SEQ ID NO: 237 and a light chain comprising SEQ ID NO: 238; or
 - x) a heavy chain comprising SEQ ID NO: 257 and a light chain comprising SEQ ID NO: 258; or
 - xi) a heavy chain comprising SEQ ID NO: 277 and a light chain comprising SEQ ID NO: 278; or
 - xii) a heavy chain comprising SEQ ID NO: 297 and a light chain comprising SEQ ID NO: 298; or
 - xiii) a heavy chain comprising SEQ ID NO: 317 and a light chain comprising SEQ ID NO: 318; or
 - xiv) a heavy chain comprising SEQ ID NO: 337 and a light chain comprising SEQ ID NO: 338; or
 - xv) a heavy chain comprising SEQ ID NO: 357 and a light chain comprising SEQ ID NO: 358; or
 - xvi) a heavy chain comprising SEQ ID NO: 377 and a light chain comprising SEQ ID NO: 378; or
 - xvii) a heavy chain comprising SEQ ID NO: 397 and a light chain comprising SEQ ID NO: 398; or
 - xviii) a heavy chain comprising SEQ ID NO: 417 and a light chain comprising SEQ ID NO: 418; or
 - xix) a heavy chain comprising SEQ ID NO: 437 and a light chain comprising SEQ ID NO: 438; or
 - xx) a heavy chain comprising SEQ ID NO: 457 and a light chain comprising SEQ ID

- NO: 458; or
- xxi) a heavy chain comprising SEQ ID NO: 477 and a light chain comprising SEQ ID NO: 478; or
 - xxii) a heavy chain comprising SEQ ID NO: 497 and a light chain comprising SEQ ID NO: 498; or
 - xxiii) a heavy chain comprising SEQ ID NO: 517 and a light chain comprising SEQ ID NO: 518; or
 - xxiv) a heavy chain comprising SEQ ID NO: 537 and a light chain comprising SEQ ID NO: 538; or
 - xxv) a heavy chain comprising SEQ ID NO: 557 and a light chain comprising SEQ ID NO: 558; or
 - xxvi) a heavy chain comprising SEQ ID NO: 577 and a light chain comprising SEQ ID NO: 578.
15. The antigen-binding fragment according to any one of the preceding claims, which is an scFv, Fab, Fab' fragment or a F(ab')₂ fragment.
16. The isolated antibody or antigen-binding fragment according to any one of the preceding claims, which is a monoclonal antibody or antigen-binding fragment thereof.
17. The isolated antibody or antigen-binding fragment according to any one of the preceding claims, which is a human, humanized or chimeric antibody or antigen-binding fragment thereof.
18. An isolated antibody or antigen-binding fragment thereof that competes with the isolated antibody or antigen-binding fragment according to any one of the preceding claims for binding to human Sema3A.
19. An antibody conjugate, comprising the isolated antibody or antigen binding fragment according to any one of the preceding claims.
20. An isolated nucleic acid sequence that encodes the antibody or antigen-binding fragment according to any one of claims 1 to 17.
21. A vector comprising a nucleic acid sequence according to claim 20.

22. An isolated cell expressing the antibody or antigen-binding fragment according to any one of claims 1 to 17 and/or comprising the nucleic acid according to claim 20 or the vector according to claim 21.
23. The isolated cell according to claim 22, wherein said cell is a prokaryotic or a eukaryotic cell.
24. A method of producing the isolated antibody or antigen-binding fragment according to any one of claims 1 to 17 comprising culturing of the cell according to any one of claims 22 or 23 and optionally purification of the antibody or antigen-binding fragment thereof.
25. A pharmaceutical composition comprising the isolated antibody or antigen-binding fragment according to any one of claims 1 to 17 or the antibody conjugate according to claim 19.
26. The isolated antibody or antigen-binding fragment according to any one of claims 1 to 17 or the conjugate according to claim 19 or the pharmaceutical composition according to claim 25 for use as a medicament.
27. The isolated antibody or antigen-binding fragment according to any one of claims 1 to 17 or the antibody conjugate according to claim 19 for use as a diagnostic agent.
28. The isolated antibody or antigen-binding fragment according to any one of claims 1 to 17 or the conjugate according to claim 19 or the pharmaceutical composition according to claim 25 for use in the treatment and/or prevention of i) renal diseases, in particular acute and chronic kidney diseases, diabetic kidney diseases, Alport syndrome, acute and chronic renal failure, polycystic kidney disease (PCKD) and syndrome of inadequate ADH secretion (SIADH); ii) sequelae of renal insufficiency, in particular pulmonary edema, heart failure, uremia, anemia, electrolyte disturbances such as hyperkalemia and hyponatremia and disturbances in bone and carbohydrate metabolism; iii) vascular hyperpermeability, diabetic retinopathy, deterioration of the blood retinal barrier, macular edema, particularly age related macular edema, non-proliferative age-related macular edema and non-proliferative diabetic macular edema; iv) diseases of the central or peripheral nervous system in particular neuropathic pain, spinal cord injury, multiple sclerosis, traumatic brain injury, brain edema and neurodegenerative diseases, particularly Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, progressive supranuclear paralysis, black substance degeneration, Shy-Drager syndrome, olivopontocerebellar atrophy and spinocerebellar degeneration; or v) cancer, in particular intestinal cancer, colorectal cancer, lung cancer, breast cancer, brain cancer, melanoma, renal cell cancer, leukemia, lymphoma, T-cell lymphoma, stomach cancer, pancreatic cancer, cervical cancer, endometrial cancer, ovarian cancer, esophageal cancer, liver cancer, squamous cell carcinoma of the head and

neck, skin cancer, urinary tract cancer, prostate cancer, choriocarcinoma, pharyngeal cancer and larynx cancer.

29. The isolated antibody or antigen-binding fragment according to any one of claims 1 to 17 or the conjugate according to claim 19 or the pharmaceutical composition according to claim 25 for use in simultaneous, separate, or sequential combination with one or more further therapeutically active compounds.
30. A kit comprising the isolated antibody or antigen-binding fragment according to any one of claims 1 to 17 or the conjugate according to claim 19 and instructions for use.